Chirabilva (Holoptelea integrifolia)

Chirabilva (Holoptelea integrifolia) is an Ayurvedic medicinal tree whose bark and leaves contain bioactive compounds including friedelin, epifriedelanol, and holoptelein that drive its therapeutic effects. These triterpenoids and flavonoids inhibit pro-inflammatory mediators, making it primarily studied for anti-inflammatory, antidiabetic, and dermatological applications.

Origin & History

Chirabilva, known scientifically as Holoptelea integrifolia, is a deciduous tree native to India, part of the Ulmaceae family. Its bark and leaves are traditionally used in Ayurveda, prepared as decoctions, powders, or pastes.

Historical & Cultural Context

Chirabilva has been used in Ayurveda for centuries to treat conditions like localized swelling, skin diseases, and diabetes. It is also employed by Indian tribes for pain and inflammation relief.

Health Benefits

• Anti-inflammatory effects, comparable to indomethacin in animal studies [1][3][5]. • Potential improvement in dermatitis with topical applications, as observed in a 2018 clinical trial in Pune [2]. • Observational reports suggest reduced joint stiffness in mild osteoarthritis [2]. • Antidiabetic effects shown in preclinical studies with alloxan-induced diabetic rats [3]. • Anthelmintic activity demonstrated against Pheretima posthuma in lab studies [3].

How It Works

The triterpenoid friedelin inhibits cyclooxygenase (COX-1 and COX-2) enzymes and suppresses NF-κB signaling, reducing downstream synthesis of prostaglandins and pro-inflammatory cytokines such as TNF-α and IL-6. Holoptelein and related alkaloids appear to modulate alpha-glucosidase and alpha-amylase activity, slowing carbohydrate digestion and attenuating postprandial glucose spikes. Topically, epifriedelanol is thought to downregulate histamine-mediated mast cell degranulation, contributing to its observed anti-dermatitic effects.

Scientific Research

There are no human randomized controlled trials or meta-analyses available for Chirabilva. Evidence is primarily based on preclinical animal studies and traditional use validations, with some observational reports indicating potential benefits.

Clinical Summary

Animal studies using carrageenan-induced paw edema models have demonstrated anti-inflammatory activity of Holoptelea integrifolia bark extract comparable to indomethacin at equivalent doses, though these findings require translation to human trials. A 2018 clinical trial conducted in Pune assessed topical Chirabilva formulations for dermatitis, reporting measurable symptom improvement, but sample size and blinding details have not been widely published, limiting interpretability. Observational reports note reduced joint stiffness in patients with mild osteoarthritis using bark decoctions, but no randomized controlled trials with defined endpoints have been completed to date. Overall, evidence is preliminary and largely preclinical; robust phase II or III human trials are lacking.

Nutritional Profile

Chirabilva (Holoptelea integrifolia) is a medicinal plant rather than a dietary food source; formal macronutrient profiling is limited, but the following is known from phytochemical and partial compositional studies: Bioactive compounds (primary focus): Bark contains holoptelin-A and holoptelin-B (lapachol-type naphthoquinones, ~0.8–1.2% dry weight), identified as key anti-inflammatory and antifungal constituents. Sitosterol and its glucoside (sitosterol-3-O-glucoside) are present in bark and leaf fractions. Friedelin (a pentacyclic triterpene) isolated from bark at trace concentrations (~0.05–0.1% dry weight). Tannins: hydrolysable tannins estimated at 4–8% in bark dry weight, contributing astringent properties. Saponins detected in leaf and stem bark extracts (~2–4% dry weight). Flavonoids including quercetin and kaempferol derivatives present in leaf extracts at approximately 1.5–3 mg/g dry weight. Alkaloids present in trace amounts in bark (not fully characterized). Phenolic acids: gallic acid and ellagic acid detected in bark aqueous extracts. Crude fiber (bark powder): approximately 18–24% dry weight based on proximate analysis of related Ulmaceae members. Protein content (leaf): estimated 8–12% dry weight, typical for leafy medicinal plant material, with limited bioavailability data. Minerals (leaf/bark, approximate): calcium ~1,200–1,800 mg/100g dry weight, iron ~15–25 mg/100g dry weight, potassium ~800–1,100 mg/100g dry weight, magnesium ~200–350 mg/100g dry weight; these values are extrapolated from regional phytochemical surveys. Vitamins: not systematically characterized; trace ascorbic acid reported in fresh leaf. Fixed oils from seeds contain oleic and linoleic acids as dominant fatty acids (~55–65% combined of total fatty acid fraction). Bioavailability notes: Holoptelin compounds show moderate lipophilicity, suggesting better absorption with lipid-based carriers; tannins may reduce mineral bioavailability when consumed orally; the plant is used primarily as a bark decoction or topical paste in Ayurvedic practice rather than as a food ingredient, so oral bioavailability data in humans is minimal and largely inferred from animal studies.

Preparation & Dosage

Traditional dosages include 30-60 ml of bark decoction for diabetes and related ailments, and topical use of bark powder for wounds. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Turmeric, Ashwagandha, Neem, Triphala, Ginger

Safety & Interactions

Chirabilva is generally considered safe at traditional Ayurvedic doses when used short-term, but systematic human safety data are absent, and high-dose oral bark extracts have shown mild gastrointestinal irritation in animal toxicity studies. Because friedelin inhibits COX enzymes, concurrent use with NSAIDs such as ibuprofen or aspirin may produce additive gastric mucosal risk or unpredictable pharmacodynamic interactions. Its alpha-glucosidase inhibitory activity raises a theoretical concern for additive hypoglycemia when combined with antidiabetic medications including metformin or sulfonylureas, requiring blood glucose monitoring. Chirabilva is not recommended during pregnancy or lactation due to complete absence of safety data in these populations, and individuals with liver or kidney disease should avoid use without medical supervision.